Loading
SYS6023 is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER3.
SYS6023 is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is HER3 (the sponsor names HER3). The sponsor states: Antibody-drug conjugate targeting HER3, administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT07597629, plans to enrol 36 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate targeting HER3, administered by intravenous infusion. Connects to HER3.
1.SYS6023's antibody arm binds HER3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SYS6023" OR ABSTRACT:"SYS6023") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SYS6023, not a curated reading list.
Shares A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer, CSPC Pharmaceutical Group, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER3, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.